Oncolytic Vaccinia Virus
First Claim
Patent Images
1. A nucleic acid sequence comprising at least three vaccinia virus promoters wherein the at least three promoters are positioned in the same orientation.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to an oncolytic vaccinia virus and virus vectors for use in cancer therapy where in the virus comprises at least three vaccinia virus promoters which are positioned in the same orientation.
-
Citations
26 Claims
- 1. A nucleic acid sequence comprising at least three vaccinia virus promoters wherein the at least three promoters are positioned in the same orientation.
-
9. (canceled)
- 13. A TK-deficient vaccinia virus comprising an inactivated N1L gene.
- 20. A composition comprising a TK-deficient vaccinia virus, wherein the virus comprises an inactivated N1L gene, said N1L gene inactivated by the insertion of a vector or nucleic acid sequence encoding a heterologous polypeptide, optionally in the presence of a pharmaceutically acceptable carrier or excipient.
-
22-23. -23. (canceled)
- 24. A method of treating cancer comprising administering to a subject a TK-deficient vaccinia virus wherein the virus comprises an inactivated N1L gene, said N1L gene inactivated by the insertion of a vector or nucleic acid sequence encoding a heterologous polypeptide.
Specification